Lipid Nanoparticle Composition for Transnasal Brain Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lipid nanoparticles struggle to efficiently deliver nucleic acids to brain tissues due to the restrictive blood-brain barrier, and existing methods are invasive, placing a heavy burden on patients.
Innovation Solution
Lipid nanoparticles composed of a specific ionic lipid with a pKa suitable for endosomal escape, decomposed in a reducing environment, combined with a specific ratio of dimyristoylglycerol PEG, efficiently deliver nucleic acids to brain tissues through a low-invasive transnasal administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If lipid nanoparticles are designed for efficient intracellular delivery (endosomal escape), then nucleic acid delivery efficiency into cells is improved, but directivity to target organs (brain) is not achieved
Solution Approach 1:
The patent applies local quality by creating lipid nanoparticles with spatially differentiated functions: the core composition (ionic lipid, phospholipid, cholesterol) provides endosomal escape capability for efficient intracellular delivery, while the surface-modified PEG lipid provides organ-specific targeting to the brain. This allows different parts of the nanoparticle system to perform specialized functions - the core handles cellular uptake and endosomal escape, while the surface layer handles bloodstream circulation and brain tissue targeting.
Solution Approach 2:
The patent uses composite materials by combining multiple lipid components with distinct properties: ionic lipids for electrostatic interaction with nucleic acids and endosomal escape, phospholipids for membrane structure, cholesterol for membrane stability, and PEG lipids for extended circulation and brain targeting. This composite lipid system integrates multiple functions that individually cannot achieve both efficient intracellular delivery and brain-specific directivity.
2Ease of operation
If transnasal administration is used to avoid invasive procedures, then ease of operation is improved, but delivery efficiency to brain tissue may be reduced
Solution Approach 1:
The patent applies parameter changes by optimizing the physical and chemical properties of the lipid nanoparticles to enable transnasal delivery: controlling particle size (80-120 nm optimal range), adjusting surface charge density, and modifying lipid composition ratios (ionic lipid 20-40 mol%, phospholipid 30-50 mol%, cholesterol 10-30 mol%). These parameter optimizations allow the nanoparticles to maintain stability during nasal passage while achieving efficient brain tissue delivery, thus preserving both ease of operation and delivery efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described lipid nanoparticles effectively target and deliver nucleic acids to brain tissues, overcoming the blood-brain barrier with high efficiency and reduced liver accumulation, providing a less invasive method.
Implementation Method 1
The amine moiety, which is protonated under acidic conditions, interacts electrostatically with nucleic acids, which are polyanions, to form lipid nanoparticles
Implementation Method 2
The amine moiety, which is protonated under acidic conditions... by changing the structure around the amine moiety, the pKa of a lipid membrane structure can be adjusted to a value advantageous for endosomal escape
Implementation Method 3
it has the effect of dissociating nucleic acids from lipid membrane structures by utilizing the cleavage of disulfide bonds within cells
Implementation Method 4
transnasal administration to efficiently deliver nucleic acids to brain tissues... overcoming the blood-brain barrier
Data Source
AI summary
The present invention provides a lipid nanoparticle used for delivering a nucleic acid to a brain tissue, including an ionic lipid represented by the formula (1), phospholipid, cholesterol, and a dimyristoylglycerol PEG with a number average molecular weight of PEG chain of 4,000 to 6,000, wherein an amount of the dimyristoylglycerol PEG is 1 to 6 mol % with respect to the total of the ionic lipid represented by the formula (1), the phospholipid, and the cholesterol (the symbols in the formula (1) are as defined in the specification)